DrugPatentWatch Database Preview
Drugs in Development Information for Papaverine
» See Plans and Pricing
What is the development status for investigational drug Papaverine?
Papaverine is an investigational drug.
There have been 16 clinical trials for Papaverine.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Erectile Dysfunction, Enuresis, and Prostatic Neoplasms. The leading clinical trial sponsors are Cairo University, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There is one US patent protecting this investigational drug and nineteen international patents.
Summary for Papaverine
US Patents | 1,942 |
International Patents | 19,157 |
US Patent Applications | 3,470 |
WIPO Patent Applications | 2,004 |
Japanese Patent Applications | 702 |
Clinical Trial Progress | Phase 3 (2019-04-01) |
Vendors | 39 |
Recent Clinical Trials for Papaverine
Title | Sponsor | Phase |
---|---|---|
Effect of Papaverine on Renal Artery Blood Flow Volume | Asan Medical Center | Phase 4 |
Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients | The University of Texas Health Science Center, Houston | Phase 4 |
Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED | Benha University | Phase 2/Phase 3 |
Clinical Trial Summary for Papaverine
Top disease conditions for Papaverine
Top clinical trial sponsors for Papaverine
US Patents for Papaverine
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Papaverine | Start Trial | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | Start Trial |
Papaverine | Start Trial | Cytochrome P450 fusion protein | The University of York (York, GB) Sun Pharmaceutical Industries (Australia) Pty Ltd (Notting Hill, Victoria, AU) | Start Trial |
Papaverine | Start Trial | Matrix and layer compositions for protection of bioactives | Novus International, Inc. (St. Charles, MO) | Start Trial |
Papaverine | Start Trial | Drug combinations and uses in treating a coughing condition | Infirst Healthcare Limited (London, GB) | Start Trial |
Papaverine | Start Trial | Non-fouling, anti-microbial, anti-thrombogenic graft compositions | ARROW INTERNATIONAL, INC. (Wayne, PA) | Start Trial |
Papaverine | Start Trial | Method of treating raynaud's disease secondary to connectivitis using aminaphtone | LABORATORI BALDACCI S.P.A. (Pisa, IT) | Start Trial |
Papaverine | Start Trial | Depot formulations | DURECT CORPORATION (Cupertino, CA) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Papaverine
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Papaverine | World Intellectual Property Organization (WIPO) | WO2014052836 | 2032-09-27 | Start Trial |
Papaverine | Australia | AU2015261278 | 2034-05-16 | Start Trial |
Papaverine | Australia | AU2019253858 | 2034-05-16 | Start Trial |
Papaverine | Canada | CA2946812 | 2034-05-16 | Start Trial |
Papaverine | European Patent Office | EP3143125 | 2034-05-16 | Start Trial |
Papaverine | United Kingdom | GB201408729 | 2034-05-16 | Start Trial |
Papaverine | United Kingdom | GB201506805 | 2034-05-16 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |